These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

588 related items for PubMed ID: 18379354

  • 1. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Piattoni S, Di Carlo L, Semeraro A, Darwish S, Tofanetti FR, Stocchi L, Mihaylova Z, Bellezza G, Del Sordo R, Daddi G, Crinò L, Tonato M.
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [Abstract] [Full Text] [Related]

  • 2. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH, Zhang SL, Li JL, Yap WS, Howe TC, Tan BP, Lee YS, Wong D, Khoo KL, Seto KY, Tan L, Agasthian T, Koong HN, Tam J, Tan C, Caleb M, Chang A, Ng A, Tan P.
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [Abstract] [Full Text] [Related]

  • 3. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M.
    Oncogene; 1998 May 14; 16(19):2469-77. PubMed ID: 9627113
    [Abstract] [Full Text] [Related]

  • 4. Topoisomerase IIalpha gene expression is regulated by the p53 tumor suppressor gene in nonsmall cell lung carcinoma patients.
    Liu D, Huang CL, Kameyama K, Hayashi E, Yamauchi A, Sumitomo S, Yokomise H.
    Cancer; 2002 Apr 15; 94(8):2239-47. PubMed ID: 12001123
    [Abstract] [Full Text] [Related]

  • 5. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.
    Tumori; 2008 Apr 15; 94(3):398-405. PubMed ID: 18705409
    [Abstract] [Full Text] [Related]

  • 6. Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.
    Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.
    Tumori; 2007 Apr 15; 93(5):473-7. PubMed ID: 18038880
    [Abstract] [Full Text] [Related]

  • 7. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
    Sirera R, Bremnes RM, Cabrera A, Jantus-Lewintre E, Sanmartín E, Blasco A, Del Pozo N, Rosell R, Guijarro R, Galbis J, Sánchez JJ, Camps C.
    J Thorac Oncol; 2011 Feb 15; 6(2):286-90. PubMed ID: 21252717
    [Abstract] [Full Text] [Related]

  • 8. Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.
    Dong S, Zhao N, Deng W, Sun HW, Niu FY, Yang JJ, Zhong WZ, Li F, Yan HH, Xu CR, Zhang QY, Yang XN, Liao RQ, Nie Q, Wu YL.
    World J Surg Oncol; 2017 Jan 09; 15(1):12. PubMed ID: 28069039
    [Abstract] [Full Text] [Related]

  • 9. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer.
    Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A.
    Br J Cancer; 2001 Jan 09; 84(2):226-31. PubMed ID: 11161381
    [Abstract] [Full Text] [Related]

  • 10. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
    He C, Liu M, Zhou C, Zhang J, Ouyang M, Zhong N, Xu J.
    Int J Cancer; 2009 Nov 15; 125(10):2393-9. PubMed ID: 19530244
    [Abstract] [Full Text] [Related]

  • 11. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer.
    Wu HH, Chu YC, Wang L, Tsai LH, Lee MC, Chen CY, Shieh SH, Cheng YW, Lee H.
    Ann Surg Oncol; 2013 Dec 15; 20 Suppl 3():S336-47. PubMed ID: 22688662
    [Abstract] [Full Text] [Related]

  • 12. XPC mRNA level may predict relapse in never-smokers with non-small cell lung cancers.
    Yeh KT, Wu YH, Lee MC, Wang L, Li CT, Chen CY, Lee H.
    Ann Surg Oncol; 2012 Mar 15; 19(3):734-42. PubMed ID: 21861227
    [Abstract] [Full Text] [Related]

  • 13. p53 gene mutations in non-small cell lung cancer detected by polymerase chain reaction single-strand conformation polymorphism analysis.
    Zhao Y, Wu D, Xiang X, Zhang B, Zhou N, Hu Y.
    Chin Med Sci J; 1999 Sep 15; 14(3):134-7. PubMed ID: 12903811
    [Abstract] [Full Text] [Related]

  • 14. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
    Sullivan I, Salazar J, Arqueros C, Andrés M, Sebio A, Majem M, Szafranska J, Martínez E, Páez D, López-Pousa A, Baiget M, Barnadas A.
    Clin Transl Oncol; 2017 Jul 15; 19(7):884-890. PubMed ID: 28150169
    [Abstract] [Full Text] [Related]

  • 15. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
    Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, Kim JH.
    J Thorac Oncol; 2013 Feb 15; 8(2):171-8. PubMed ID: 23287850
    [Abstract] [Full Text] [Related]

  • 16. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC, Chen CY, Chen SK, Cherng SH, Ho WL, Lee H.
    Cancer Res; 1998 Jan 15; 58(2):328-33. PubMed ID: 9443413
    [Abstract] [Full Text] [Related]

  • 17. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
    Vinayanuwattikun C, Sriuranpong V, Tanasanvimon S, Chantranuwat P, Mutirangura A.
    J Thorac Oncol; 2011 Nov 15; 6(11):1818-25. PubMed ID: 21964525
    [Abstract] [Full Text] [Related]

  • 18. Comparison of mutational changes in involved N1 lymph nodes with those in primary tumors in stage II non-small cell lung cancer: a pilot study.
    Fernando HC, Sasatomi E, Christie NA, Buenaventura PO, Finkelstein SD, Yousem SA, Soose R, Close JM, Luketich JD.
    J Thorac Cardiovasc Surg; 2004 Jan 15; 127(1):87-91. PubMed ID: 14752417
    [Abstract] [Full Text] [Related]

  • 19. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J, Hu YM, Wang Y, Tang XP, Shi WL, Du YJ.
    Int J Biol Markers; 2014 Dec 09; 29(4):e328-36. PubMed ID: 24519547
    [Abstract] [Full Text] [Related]

  • 20. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
    Chien WP, Wong RH, Cheng YW, Chen CY, Lee H.
    Ann Surg Oncol; 2010 Apr 09; 17(4):1194-202. PubMed ID: 19941079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.